John P. Mulhall, MD, discusses the significant sexual and non-sexual adverse events of low testosterone resulting from using androgen deprivation therapy (ADT) to treat men with prostate cancer. He emphasizes the need for physicians to counsel patients on long-term expectations and to obtain fully-informed consent prior to the initiation of this therapy.
Read more here: [ Ссылка ]
![](https://s2.save4k.ru/pic/u4TN9mCHlg4/mqdefault.jpg)